Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised $315 million by offering 17.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to raise $200 million, before it...read more
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Boston, MA-based company now plans to raise $250 million by offering 14.7 million shares at a...read more
Updated Monday 9/9/24 Three biotechs are scheduled to complete IPOs this week. Bicara Therapeutics (BCAX) plans to raise $200 million at an $865 million market cap. Its lead candidate, ficerafusp alfa, is a bifunctional...read more
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, announced terms for its IPO on Friday. The Boston, MA-based company plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. At...read more
Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised $315 million by offering 17.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to raise $200 million, before it...read more
Oncology biotech Bicara Therapeutics increases shares offered 25% ahead of $250 million IPO
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Boston, MA-based company now plans to raise $250 million by offering 14.7 million shares at a...read more
US IPO Week Ahead: A trio of biotechs kick off fall IPO market
Updated Monday 9/9/24 Three biotechs are scheduled to complete IPOs this week. Bicara Therapeutics (BCAX) plans to raise $200 million at an $865 million market cap. Its lead candidate, ficerafusp alfa, is a bifunctional...read more
Oncology biotech Bicara Therapeutics sets terms for $200 million IPO
Bicara Therapeutics, a Phase 1 biotech developing a bifunctional antibody to target solid tumors, announced terms for its IPO on Friday. The Boston, MA-based company plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. At...read more